Veloxis Pharmaceuticals A/S, of Horsholm, Denmark, said Envarsus, a once-daily formulation of immunosuppressive drug tacrolimus using the company’s Meltdose technology, was granted orphan status by the FDA for the prevention of organ rejection in patients receiving allogenic kidney transplants.